

CATIONIC OLIGOMER OF A SACCHARIDE FOR RESOLVING ENANTIOMERS  
AND ASYMMETRIC SYNTHESIS

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of United States  
5 Provisional Application No. 60/529,112, filed December 15,  
2003, which is incorporated herein by reference.

FIELD OF THE INVENTION

The present invention relates to a cationic oligomer  
of a saccharide for resolving enantiomers. In particular, the  
10 invention relates to a cationic cyclodextrin for resolving  
enantiomers.

BACKGROUND OF THE INVENTION

The resolution of racemic compounds has attracted  
great interest in analytical chemistry, especially in  
15 pharmaceutical analysis. Many isomeric pharmaceutical drugs  
frequently exhibit some stereoselectivity for pharmacological  
activity. Therefore, the separation of enantiomeric mixtures  
is one of the most important issues in pharmaceutical  
development. Furthermore, rapid, sensitive and selective  
20 analytical methods are required to control the chiral purity  
of the products.

Natural cyclodextrins (CD) and their derivatives are  
extensively used as chiral agents in separation and  
purification processes such as liquid chromatography (LC),  
25 high performance liquid chromatography (HPLC), capillary  
electrophoresis (CE) and super- and sub-critical fluid  
chromatography (SFC) due to their unique property to form  
inclusion complexes with other smaller hydrophobic molecules  
[1-4].

The use of an ionic cyclodextrin as a chiral agent in chromatography has shown great potential as an efficient chiral agent, offering enhanced discrimination for many chiral drugs. Additionally, ionic CDs have been shown to be 5 effective in controlling enantiomer migration order in chromatography, however, the degree of substitution of an ionic CD has a critical effect on the resolution of the optical isomers [5-8].

Capillary electrophoresis (CE) has become a powerful 10 tool for enantiomeric separations during the last decade. Concerning enantiomeric separation by CE, a simple theoretical model using cyclodextrin as a chiral agent was first proposed by S. A. C. Wren and R. C. Rowe [9]. Native CDs and derivatives have been widely accepted as chiral agents due to 15 their characteristics of high water solubility, weak UV absorption and excellent chiral discrimination toward various aromatic enantiomers [10]. However, all enantiomers are not always separated with native CDs or their derivatives because they are electrically neutral. One limitation of neutral CDs as chiral agents is that neutral racemates cannot be resolved 20 unless a different discrimination mechanism such as ionic micellar solubilization is added [11].

The use of an ionic CD offers new possibilities to 25 separate neutral racemates because an ionic CD can move in the opposite direction to an analyte and shows capability as an ion-pairing agent and thus enhancing the resolution of enantiomers [12]. Ionic CDs have several advantages for the enantiomer separations over natural CDs. Strong electrostatic interactions between an ionic CD and an oppositely charged 30 analyte are effective for the formation of an inclusion complex. Also, the large difference in electrophoretic

mobility between a free analyte and an inclusion complex enhance enantiomeric resolution [13].

Ionic cyclodextrins that are commonly used in chromatography can be classified as anionic, cationic, and 5 amphoteric or zwitterionic. A commercial amphoteric  $\beta$ -CD (AM- $\beta$ -CD) such as carboxymethyl hydroxypropyltrimethylammonium- $\beta$ -CD has both cationic and anionic substituents [14]. When the degree of substitution is equal between cationic and anionic substituents, the CDs have no net charge in a buffer solution 10 unless the pH is extremely low or high. It is not known whether these CDs are charged or not in buffer solution.


At present, more anionic than cationic cyclodextrin derivatives are used in chiral chromatography separations. Although cationic derivatives have been synthesized 15 previously, they were not often used in separation. For example, an amino-functionalized cyclodextrin was used as a model for studying enzymatic biological processes involving a positively charged group in the vicinity of the active site [15] and mono-6-(alkylamino)- $\beta$ -cyclodextrins also have been 20 used for studying the mechanism of cooperative binding of organic guests by aggregated cationic alkyl cyclodextrin [16].

The earliest cationic cyclodextrin derivatives to be used for CE applications were mono-(6- $\beta$ -aminoethylamino-6-deoxy)- $\beta$ -cyclodextrin [17], 6<sup>A</sup>-methylamino and 6<sup>A,D</sup>-dimethylamino- $\beta$ -cyclodextrins [18], 6-amino- $\beta$ -cyclodextrin 25 [19] and 6-ethylenediamine- $\beta$ -cyclodextrin [20]. A commercial quaternary ammonium hydroxypropyl- $\beta$ -cyclodextrin (QA- $\beta$ -CD), a randomly functionalized CD with a degree of substitution of three to five groups, has been successfully used as chiral 30 selector for enantiomer separations of various acidic racemates by CE [14]. As compared to neutral CD derivatives,

QA- $\beta$ -CD is effective for the enantiomer separations at low concentration below 5 mM due to the strong electrostatic interaction between cationic CD and anionic analytes. However, the QA- $\beta$ -CD is not useful for the enantiomer separation of hydrophobic compounds such as arylpropionic acid and warfarin because of too strong interactions with the CD due to the degree of substitution. The substitution distribution significantly influences the enantioselectivity and peak shapes. Therefore, pure single charged CD derivatives (DS = 1) as chiral agents should provide a high plate number and good reproducibility for enantiomer separations by CE.

#### SUMMARY OF THE INVENTION

According to one aspect of the present invention, there is provided a cationic oligomer of a saccharide of the general formula (I)



wherein  $n = 0$  to 8;

X is nitrogen or phosphorous;


R is a hydroxyl, an ester, a carbamate, a carbonate, a phosphinate, a phosphonate, a phosphate, a sulfinate, a sulfite, a sulfonate, a sulphate, or R'O-, wherein R' is

5 linear or branched (C<sub>1</sub>-C<sub>20</sub>)alkyl, hydroxy(C<sub>1</sub>-C<sub>20</sub>)alkyl, carboxy(C<sub>1</sub>-C<sub>20</sub>)alkyl, aryl, or aryl(C<sub>1</sub>-C<sub>20</sub>)alkyl; and

R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are each independently selected from the group consisting of hydrogen, linear or branched (C<sub>1</sub>-C<sub>20</sub>)alkyl, linear or branched (C<sub>1</sub>-C<sub>20</sub>)alkenyl, linear or branched (C<sub>1</sub>-

10 C<sub>20</sub>)alkynyl, and cycloalkyl; or

R<sub>1</sub> is absent, and R<sub>2</sub> and R<sub>3</sub> are taken together with X to form a ring having the following structure:



wherein m = 0 or 1;

15 Y is carbon or nitrogen;


R<sub>4</sub> is hydrogen, linear or branched (C<sub>1</sub>-C<sub>20</sub>)alkyl, linear or branched (C<sub>1</sub>-C<sub>20</sub>)alkenyl, linear or branched (C<sub>1</sub>-C<sub>20</sub>)alkynyl, or cycloalkyl; and

R<sub>5</sub> is hydrogen, 2-(2-ethoxyethoxy)ethyl, linear or branched

20 (C<sub>1</sub>-C<sub>20</sub>)alkyl, linear or branched (C<sub>1</sub>-C<sub>20</sub>)alkenyl, linear or branched (C<sub>1</sub>-C<sub>20</sub>)alkynyl, cycloalkyl, or NR<sub>6</sub>R<sub>7</sub>, wherein R<sub>6</sub> and R<sub>7</sub> are each independently selected from the group consisting of hydrogen, linear or branched (C<sub>1</sub>-C<sub>20</sub>)alkyl, linear or branched (C<sub>1</sub>-C<sub>20</sub>)alkenyl, linear or branched (C<sub>1</sub>-C<sub>20</sub>)alkynyl, and

25 cycloalkyl.

According to another aspect of the present invention, there is provided a cationic oligomer of a saccharide of the general formula (I)




5 wherein  $n = 0$  to 8;

X is nitrogen or phosphorous;

R is a hydroxyl, an ester, a carbamate, a carbonate, a phosphinate, a phosphonate, a phosphate, a sulfinate, a sulfite, a sulfonate, a sulphate, or  $R' O^-$ , wherein  $R'$  is  
 10 linear or branched ( $C_1-C_{20}$ ) alkyl, hydroxy( $C_1-C_{20}$ ) alkyl, carboxy( $C_1-C_{20}$ ) alkyl, aryl, or aryl( $C_1-C_{20}$ ) alkyl; and

$R_1$ ,  $R_2$  and  $R_3$  are each independently selected from the group consisting of hydrogen, linear or branched( $C_1-C_{20}$ ) alkyl, linear or branched( $C_1-C_{20}$ ) alkenyl, linear or branched( $C_1-C_{20}$ ) alkynyl,  
 15 and cycloalkyl.

According to yet another aspect of the present invention, there is provided a cationic oligomer of a saccharide of the general formula (II)




5 wherein n = 0 to 8;

R is a hydroxyl, an ester, a carbamate, a carbonate, a phosphinate, a phosphonate, a phosphate, a sulfinate, a sulfite, a sulfonate, a sulphate, or R'O-, wherein R' is linear or branched (C<sub>1</sub>-C<sub>20</sub>)alkyl, hydroxy(C<sub>1</sub>-C<sub>20</sub>)alkyl, 10 carboxy(C<sub>1</sub>-C<sub>20</sub>)alkyl, aryl, or aryl(C<sub>1</sub>-C<sub>20</sub>)alkyl; and

R<sub>4</sub> is hydrogen, linear or branched (C<sub>1</sub>-C<sub>20</sub>)alkyl, linear or branched (C<sub>1</sub>-C<sub>20</sub>)alkenyl, linear or branched (C<sub>1</sub>-C<sub>20</sub>)alkynyl, or cycloalkyl; and

R<sub>5</sub> is hydrogen, 2-(2-ethoxyethoxy)ethyl, linear or branched (C<sub>1</sub>-C<sub>20</sub>)alkyl, linear or branched (C<sub>1</sub>-C<sub>20</sub>)alkenyl, linear or branched (C<sub>1</sub>-C<sub>20</sub>)alkynyl, or cycloalkyl.

According to still another aspect of the present invention, there is provided a cationic oligomer of a saccharide of the general formula (III)



5 wherein n = 0 to 8;

R is a hydroxyl, an ester, a carbamate, a carbonate, a phosphinate, a phosphonate, a phosphate, a sulfinate, a sulfite, a sulfonate, a sulphate, or R'O-, wherein R' is linear or branched (C<sub>1</sub>-C<sub>20</sub>) alkyl, hydroxy(C<sub>1</sub>-C<sub>20</sub>) alkyl, 10 carboxy(C<sub>1</sub>-C<sub>20</sub>) alkyl, aryl, or aryl(C<sub>1</sub>-C<sub>20</sub>) alkyl; and

15 R<sub>5</sub> is hydrogen, linear or branched (C<sub>1</sub>-C<sub>20</sub>) alkyl, linear or branched (C<sub>1</sub>-C<sub>20</sub>) alkenyl, linear or branched (C<sub>1</sub>-C<sub>20</sub>) alkynyl, cycloalkyl, or NR<sub>6</sub>R<sub>7</sub>, wherein R<sub>6</sub> and R<sub>7</sub> are each independently selected from the group consisting of hydrogen, linear or branched (C<sub>1</sub>-C<sub>20</sub>) alkyl, linear or branched (C<sub>1</sub>-C<sub>20</sub>) alkenyl, linear or branched (C<sub>1</sub>-C<sub>20</sub>) alkynyl, and cycloalkyl.

According to a further aspect of the present invention, there is provided a method of preparing a cationic

oligomer of a saccharide, as defined herein, comprising reacting an amine, a phosphine, an imidazole, or a pyridine with a oligomer of a saccharide having a leaving group.

According to another aspect of the present  
5 invention, there is provided a use of a cationic oligomer of a saccharide, as defined herein, as chiral agent for resolving enantiomers by a chromatographic method.

According to another aspect of the present  
invention, there is provided a use of a cationic oligomer of a  
10 saccharide, as defined herein, as a chiral agent for an  
asymmetric synthesis.

#### BRIEF DESCRIPTION OF THE DRAWINGS

In order that the present invention may be more  
clearly understood, preferred embodiments thereof will now be  
15 described in detail by way of example, with reference to the  
accompanying drawings, in which:

Figures 1, 2 and 3 are chromatograms depicting the  
CE enantioseparation of racemates using methylimidazolium- $\beta$ -  
cyclodextrin as chiral agent;

20 Figures 4, 5 and 6 are chromatograms depicting the  
CE enantioseparation of racemates using allylammonium- $\beta$ -  
cyclodextrin as chiral agent;

Figures 7, 8, and 9 are chromatograms depicting the  
CE enantioseparation of racemates using propylammonium- $\beta$ -  
25 cyclodextrin as chiral agent;

Figure 10, 11 and 12 are chromatograms depicting the  
CE enantioseparation of racemates using pentylammonium- $\beta$ -  
cyclodextrin as chiral agent; and

Figure 13 depicts asymmetric reactions using a cationic oligomer of a saccharide, for example a cationic cyclodextrin, as a chiral agent.

#### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

5 The present invention makes use of a cationic oligomer of a saccharide for resolving enantiomers. The cationic oligomer of a saccharide may be straight-chained or cyclic, and functionalized by a cationic group such as an ammonium, phosphonium, imidazolium, or pyridinium group.

10 Preferably, the cationic oligomer of a saccharide is singly charged.

Examples of a saccharide include, without limitation, glucose, fructose, mannose, galactose, ribose, arabinose, xylose, lyxose, erythrose and threose. The 15 preferred saccharide is glucose. The glucose moiety may be functionalized at any one of the 2-, 3-, or 6-positions by the cationic group.

Additionally, any hydroxyl group of the cationic oligomer of a saccharide may be modified. Examples of 20 suitable modifications are linear or branched chain (C<sub>1</sub>-C<sub>20</sub>)alkyl, hydroxy(C<sub>1</sub>-C<sub>20</sub>)alkyl, carboxy(C<sub>1</sub>-C<sub>20</sub>)alkyl, aryl, aryl(C<sub>1</sub>-C<sub>20</sub>)alkyl, ester, carbamate, carbonate, phosphinate, phosphonate, phosphate, sulfinate, sulfite, sulfonate, and sulphate.

25 Preferably, the cationic oligomer of a saccharide is a cyclic cationic oligomer of a saccharide, especially a cationic cyclodextrin. The cyclic cationic oligomer of a saccharide preferably comprises 5 to 13 glucose moieties, and most preferably comprises 6 to 8 glucose moieties. However, a 30 straight-chained cationic oligomer such as a cationic


cellulose, amylose or pullulan is also contemplated. They may be used in the form of their ester, for example cellulose acetate.

The term "alkyl" refers to the radical of saturated aliphatic groups, including straight chain alkyl groups, branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups. Typical alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, hexyl, etc. The alkyl groups can be (C<sub>1</sub>-C<sub>20</sub>) alkyl. A "substituted alkyl" has substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, halogen, hydroxyl, carbonyl (such as carboxyl, ketones (including alkylcarbonyl and arylcarbonyl groups), and esters (including alkyloxycarbonyl and aryloxycarbonyl groups)), thiocarbonyl, acyloxy, alkoxy, phosphoryl, phosphonate, phosphinate, amino, acylamino, amido, amidine, imino, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, heterocyclyl, aralkyl, or an aromatic or heteroaromatic moiety. The moieties substituted on the hydrocarbon chain can themselves be substituted, if appropriate. For instance, the substituents of a substituted alkyl may include substituted and unsubstituted forms of aminos, azidos, iminos, amidos, phosphoryls (including phosphonates and phosphinates), sulfonyls (including sulfates, sulfonamidos, sulfamoyls and sulfonates), and silyl groups, as well as ethers, alkylthios, carbonyls (including ketones, aldehydes, carboxylates, and esters), -CF<sub>3</sub>, -CN and the like.

Exemplary substituted alkyls are described below. Cycloalkyls can be further substituted with alkyls, alkenyls, alkoxy, alkylthios, aminoalkyls, carbonyl-substituted alkyls, -CF<sub>3</sub>, -CN, and the like.

The terms "alkenyl" and "alkynyl" refer to unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond respectively. An "alkenyl" 5 is an unsaturated branched, straight chain, or cyclic hydrocarbon radical with at least one carbon-carbon double bond. The radical can be in either the *cis* or *trans* conformation about the double bond(s). Typical alkenyl groups include, but are not limited to, ethenyl, propenyl, 10 isopropenyl, butenyl, isobut enyl, *tert*-butenyl, pentenyl, hexenyl, etc. An "alkynyl" is an unsaturated branched, straight chain, or cyclic hydrocarbon radical with at least one carbon-carbon triple bond. Typical alkynyl groups include, but are not limited to, ethynyl, propynyl, butynyl, 15 isobutynyl, pentynyl, hexynyl, etc.


In a preferred embodiment, the cationic oligomer of a saccharide may be of the general formula (I)



wherein X is preferably nitrogen or phosphorous, and n is preferably 0 to 8, and more preferably 1 to 3.

The R group may be a hydroxyl, an ester, a carbamate, a carbonate, a phosphinate, a phosphonate, a phosphate, a sulfinate, a sulfite, a sulfonate, a sulphate, or R'O-, wherein R' is linear or branched (C<sub>1</sub>-C<sub>20</sub>)alkyl, hydroxy(C<sub>1</sub>-C<sub>20</sub>)alkyl, carboxy(C<sub>1</sub>-C<sub>20</sub>)alkyl, aryl, or aryl(C<sub>1</sub>-C<sub>20</sub>)alkyl.

The R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> groups are each independently selected from the group consisting of hydrogen, linear or branched(C<sub>1</sub>-C<sub>20</sub>)alkyl, linear or branched(C<sub>1</sub>-C<sub>20</sub>)alkenyl, linear or branched(C<sub>1</sub>-C<sub>20</sub>)alkynyl, or cycloalkyl. Alternatively, R<sub>1</sub> is absent, and R<sub>2</sub> and R<sub>3</sub> are taken together with X to form a ring having the following structure:



15

wherein Y is preferably carbon or nitrogen, and m is preferably 0 or 1.


The R<sub>4</sub> group may be selected from hydrogen, linear or branched (C<sub>1</sub>-C<sub>20</sub>)alkyl, linear or branched (C<sub>1</sub>-C<sub>20</sub>)alkenyl, linear or branched (C<sub>1</sub>-C<sub>20</sub>)alkynyl, or cycloalkyl.



The R<sub>5</sub> group may be hydrogen, 2-(2-ethoxyethoxy)ethyl, linear or branched (C<sub>1</sub>-C<sub>20</sub>)alkyl, linear or branched (C<sub>1</sub>-C<sub>20</sub>)alkenyl, linear or branched (C<sub>1</sub>-C<sub>20</sub>)alkynyl, cycloalkyl, or NR<sub>6</sub>R<sub>7</sub>, wherein R<sub>6</sub> and R<sub>7</sub> are each independently selected from the group consisting of hydrogen, linear or

branched ( $C_1$ - $C_{20}$ )alkyl, linear or branched ( $C_1$ - $C_{20}$ )alkenyl, linear or branched ( $C_1$ - $C_{20}$ )alkynyl, and cycloalkyl.

The cationic cyclodextrin (I) may also be a salt thereof comprising a counterion. A preferred counterion may 5 be selected from the group consisting of fluoride, chloride, bromide, iodide, nitrate,  $HCO_3^-$ ,  $CO_3^{2-}$ ,  $HSO_4^-$ ,  $BF_4^-$ ,  $BCl_4^-$ ,  $PF_6^-$ ,  $SbF_6^-$ ,  $AsF_6^-$ ,  $AlCl_4^-$ ,  $R_9-CO_2^-$  and  $R_9-SO_3^-$ , wherein  $R_9$  is a hydrogen, linear or branched ( $C_1$ - $C_{20}$ )alkyl, linear or branched 10 ( $C_1$ - $C_{20}$ )alkenyl, linear or branched ( $C_1$ - $C_{20}$ )alkynyl, cycloalkyl, or aryl ( $C_1$ - $C_{20}$ )alkyl.

In further preferred embodiments, the cationic cyclodextrin may be of the general formula (I), (II), and (III) :





wherein n is preferably 0 to 8, and more preferably 1 to 3.

5 When n is any one of 1 to 3, the cationic cyclodextrin is referred to as an  $\alpha$ -,  $\beta$ - and  $\gamma$ -cyclodextrin, respectively.

The cationic cyclodextrin (I) is mono-functionalized by an ammonium or a phosphonium group, the cationic cyclodextrin (II) is mono-functionalized by an imidazolium group, and the cationic cyclodextrin (III) is mono-functionalized by a 5 pyridinium group. In each case, the cyclodextrin is mono-functionalized at the 6-position, however functionalization at the 2- and 3-position is also contemplated.

The R group may be a hydroxyl, an ester, a carbamate, a carbonate, a phosphinate, a phosphonate, a 10 phosphate, a sulfinate, a sulfite, a sulfonate, a sulphate, or R'O-, wherein R' is linear or branched (C<sub>1</sub>-C<sub>20</sub>)alkyl, hydroxy(C<sub>1</sub>-C<sub>20</sub>)alkyl, carboxy(C<sub>1</sub>-C<sub>20</sub>)alkyl, aryl, or aryl(C<sub>1</sub>-C<sub>20</sub>)alkyl.

The R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> groups are preferably each 15 independently selected from the group consisting of hydrogen, linear or branched (C<sub>1</sub>-C<sub>20</sub>)alkyl, linear or branched (C<sub>1</sub>-C<sub>20</sub>)alkenyl, linear or branched (C<sub>1</sub>-C<sub>20</sub>)alkynyl, or cycloalkyl.


The R<sub>4</sub> group is preferably hydrogen, linear or branched (C<sub>1</sub>-C<sub>20</sub>)alkyl, linear or branched (C<sub>1</sub>-C<sub>20</sub>)alkenyl, 20 linear or branched (C<sub>1</sub>-C<sub>20</sub>)alkynyl, or cycloalkyl, and more preferably a hydrogen or methyl group.

The R<sub>5</sub> group is preferably hydrogen, 2-(2-ethoxyethoxy)ethyl, linear or branched (C<sub>1</sub>-C<sub>20</sub>)alkyl, linear or branched (C<sub>1</sub>-C<sub>20</sub>)alkenyl, linear or branched (C<sub>1</sub>-C<sub>20</sub>)alkynyl, 25 cycloalkyl or NR<sub>6</sub>R<sub>7</sub>, whereby R<sub>6</sub> and R<sub>7</sub> are each independently selected from the group consisting of hydrogen, linear or branched (C<sub>1</sub>-C<sub>20</sub>)alkyl, linear or branched (C<sub>1</sub>-C<sub>20</sub>)alkenyl, linear or branched (C<sub>1</sub>-C<sub>20</sub>)alkynyl, or cycloalkyl.

The cationic cyclodextrin (I), (II), or (III) may 30 also be a salt thereof comprising a counterion. A preferred

counterion is selected from the group consisting of fluoride, chloride, bromide, iodide, nitrate,  $\text{HCO}_3^-$ ,  $\text{CO}_3^{2-}$ ,  $\text{HSO}_4^-$ ,  $\text{BF}_4^-$ ,  $\text{BCl}_4^-$ ,  $\text{PF}_6^-$ ,  $\text{SbF}_6^-$ ,  $\text{AsF}_6^-$ ,  $\text{AlCl}_4^-$ ,  $\text{R}_9\text{-CO}_2^-$  and  $\text{R}_9\text{-SO}_3^-$ , wherein  $\text{R}_9$  is a linear or branched ( $\text{C}_1\text{-C}_{20}$ )alkyl, linear or branched ( $\text{C}_1\text{-C}_{20}$ )alkenyl, linear or branched ( $\text{C}_1\text{-C}_{20}$ )alkynyl, cycloalkyl, or ( $\text{C}_1\text{-C}_{20}$ )alkyl aryl.

A method for preparing a cationic oligomer of a saccharide comprises the reaction of an amine, a phosphine, an imidazole, or a pyridine with a oligomer of a saccharide 10 functionalized by a leaving group. Preferably, the amine, phosphine, imidazole, and pyridine are



wherein  $\text{R}_1$ ,  $\text{R}_2$ ,  $\text{R}_3$ ,  $\text{R}_4$ ,  $\text{R}_5$  and  $\text{R}_6$  are defined herein.

The cationic oligomer of a saccharide may be, for 15 example, a cationic oligomer of a glucose, wherein a hydroxyl group of the glucose moiety of a cyclodextrin is converted to a leaving group at the 2-, 3-, or 6-position, preferably at the 6-position.

Examples of a leaving group include, without 20 limitation, a mesylate, a tosylate, a triflate, a haloformate ester or a halide group, such as iodide, bromide, or chloride.

Examples of reagents that can be used to convert a hydroxyl group of the glucose moiety to a leaving group include, without limitation,  $\text{SOCl}_2$ ,  $\text{PBr}_3$ , tosyl chloride, mesyl 25 chloride, triflic anhydride, and an ester of chloroformic acid.

Preferably, only the hydroxyl groups at the 6-position of the glucose moieties are converted to leaving groups. Conversion of hydroxyl groups at the 2- and 3-positions, in addition to the 6-position, to leaving groups, 5 is also, however, within the scope of the invention. Conversion of hydroxyl groups at the 2-, 3- or 6-positions may be partial or complete.

As primary hydroxyl groups react more readily than secondary hydroxyl groups, it is possible to ensure that only 10 the primary hydroxyl groups are converted to leaving groups by selection of the appropriate molar ratios of reagent to hydroxyl groups. Preferably only some of the primary hydroxyl groups of the glucose moieties of the oligomer of a saccharide are converted to leaving groups, and more preferably, only one 15 of the primary hydroxyl groups is converted to a leaving group.

In the case where conversion of a hydroxyl group at the 2- or 3-position is desired, it is preferred that only one of the 2- or 3-positions is converted to a leaving group. 20 Preferably only some of the hydroxyl groups of the glucose moieties of the oligomer of a saccharide are converted to leaving groups, and more preferably, only one of the hydroxyl groups is converted to a leaving group.

Once functionalized cationically, any remaining 25 hydroxyl groups at the 2-, 3- and 6-carbon atom positions of the glucose moieties of the cationic oligomer of a saccharide may be modified by a protecting group. These remaining hydroxyl groups may be partially or fully functionalized. The expression "fully-functionalized" as used herein indicates 30 that all of the hydroxyl groups of the glucose moieties have been either protected with a protecting group or derivatized

with a derivatizing agent. It is to be appreciated, however, that the functionalizing or derivatizing reaction may not go entirely to completion, so there may be one or more hydroxyl groups still present. Alternatively, the hydroxyl group of a 5 oligomer of a saccharide may be modified before addition of a cationic group.

The remaining hydroxyl groups of the cationic oligomer of a saccharide may be functionalized to form, for example, an alkoxy, an aryloxy, an arylalkyloxy, an ester, a 10 carbamate, a carbonate, a phosphinate, a phosphonate, a phosphate, a sulfinate, a sulfite, a sulfonate or a sulphate.

If the hydroxyl group is to be converted to alkoxy, aryloxy or arylalkyloxy, it could be done, for example, by alkylating with a compound of formula (V):




wherein  $R_{10}$  is an alkyl, an aryl or an arylalkyl group, and Y is a leaving group, for example, a halide such as iodide, bromide or chloride, or a tosylate, a mesylate or a triflate.

If the hydroxyl group is to be converted to an ester 20 or a carbonate, it could be done, for example, by acylating with a compound of formula (VI):



wherein  $R_{11}$  is an alkyl, an aryl, an arylalkyl, an alkoxy, an aryloxy, or an arylalkyloxy group, and Y is as defined above; 25 or by acylating them with a compound of formula (VII):



wherein  $R_{12}$  and  $R_{13}$  are independently an alkyl, an aryl, an arylalkyl, an alkoxy, an aryloxy, or an arylalkyloxy group.

If the hydroxyl group is to be converted to a carbamate, it could be done, for example, by reacting with a compound of formula (VIII):




where  $R_{14}$  is an alkyl, an aryl or an arylalkyl group.

If the hydroxyl group is to be converted to a phosphinate, a phosphonate, or a phosphate, it could be done, for example, by reacting with a compound of formula (IX):



where  $R_{15}$  and  $R_{16}$  are, independently, hydrogen, an alkyl, an aryl, an arylalkyl, an alkoxy, an aryloxy, or an arylalkyloxy group, and  $Y$  is as defined above.

If the hydroxyl group is to be converted to a sulfinate or a sulfite, it could be done, for example, by reacting with a compound of formula (X):



20 or conversion to a sulfonate or a sulfate group by reacting them with a compound of formula (XI):




wherein  $\text{R}_{17}$  is an alkyl, an aryl, an arylalkyl, an alkoxy, an aryloxy, or an arylalkyloxy group, and  $\text{Y}$  is as defined above.

Any of the hydroxyl groups that are to be  
 5 functionalized are preferably functionalized using a large  
 molar excess of functionalizing agent in order to promote full  
 functionalization. Preferably, the excess is in the range of  
 from about 10:1 to about 50:1, more preferably from about 20:1  
 to about 40:1.

10 In a particularly advantageous embodiment of the  
 invention there is a method of preparing a cationic oligomer  
 of a saccharide by an almost quantitative reaction of pre-  
 synthesized regiodefined monotosylated cyclodextrin with an  
 amine, a phosphine, an imidazole, or a pyridine. Mono-  
 15 tosylcyclodextrins are important precursors for a variety of  
 modified cyclodextrins because a nucleophile can attack the  
 electrophilic carbon atom at the 6- and 2-positions to produce  
 a corresponding functionalized cyclodextrin [21]. A  
 nucleophilic displacement of the tosyl group by any one of an  
 20 amine, a phosphine, an imidazole or a pyridine affords a  
 cationic ammonium, phosphonium, imidazolium or pyridinium  
 cyclodextrin, respectively.

Preferably, the amine, phosphine, imidazole, and  
 pyridine are

25



wherein  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$  and  $R_6$  are defined herein.

In a further preferred embodiment, the invention makes use of a cationic oligomer of a saccharide, as defined herein, as chiral agent for resolving enantiomers by a 5 chromatographic method. Preferably, the cationic oligomer of a saccharide is based on a cationic cyclodextrin derivative as described herein for use as the chiral agent.

The chromatographic method is preferably selected from the group consisting of gas chromatography (GC), liquid 10 chromatography (LC), high performance liquid chromatography (HPLC), capillary electrophoresis (CE), and sub- or super-critical fluid chromatography (SFC).

Figures 1-9 are capillary electrophoresis (CE) chromatograms showing the enantioseparation of the racemates 15 of a number of compounds. The symbols  $t_1$  and  $t_2$  are the migration times of the enantiomers measured in minutes and  $R$  is the resolution for a pair of enantiomers.

Specifically, Figure 1, 2 and 3 are three chromatograms illustrating the enantioseparation of the 20 racemates of each 3-phenylbutyric acid, dansyl phenylalanine and dansyl aminobutyric acid, respectively, using methylimidazolium- $\beta$ -cyclodextrin as a chiral agent in a buffer having a pH between 7.5 and 8.7.

Figure 4, 5 and 6 are the three chromatograms 25 illustrating the enantioseparation of the racemates of each dansyl norvaline, dansyl norleucine and dansyl threonine, respectively, using butylimidazolium- $\beta$ -cyclodextrin as a chiral agent in a buffer having a pH of 9.6.

Figure 7, 8 and 9 are three chromatograms 30 illustrating the enantioseparation of the racemates of each

mandelic acid, dansyl DL-phenylalanine and 3-hydroxy-4-methoxy mandelic acid, respectively, using propylammonium- $\beta$ -cyclodextrin as chiral selector in buffers having a pH of 6.5.

Figure 10, 11 and 12 are three chromatograms illustrating the enantioseparation of the racemates of each dansyl DL-phenylalanine, 4-hydroxy-3-methoxy mandelic acid and 3-hydroxy-4-methoxy mandelic acid, respectively, using pentylammonium- $\beta$ -cyclodextrin as chiral selector in buffers having a pH of 6.5.

Further application of the cationic oligomer of a saccharide, such as the cationic cyclodextrin, is their use for asymmetric synthesis, for example, in reduction and pericyclic reactions, eg. ene reaction, Diel Alder reaction.

Figure 13 illustrates the asymmetric reaction of aryl aldehydes and aryl ketones using a cationic oligomer of a saccharide such as cationic cyclodextrin. In the first reaction scheme, allylation of an aryl aldehyde occurs using tetraallyl tin and a cationic oligomer of a saccharide such as cationic cyclodextrin to produce a chiral secondary alcohol in 15% enantiomeric excess. In the second reaction scheme, reduction of an aryl ketone occurs using sodium borohydride and a cationic oligomer of a saccharide such as cationic cyclodextrin to produce a chiral secondary alcohol in 10% enantiomeric excess.

## 25 Examples

The following examples are provided to illustrate the invention. It will be understood, however, that the specific details given in each example have been selected for the purpose of illustration and are not to be construed as limiting in scope of the invention.

5  $\beta$ -Cyclodextrin monofunctionalized with a tosyl group at the 6-position was prepared using the previously reported procedure by B. Brady, N. Lynam, T. O'Sullivan, C. Ahern, and R. Darcy, [22], and at the 2-position was prepared using the previously reported procedure by T. Murakami, K. Harata, and S. Morimoto [23].

Alkylimidazolium- $\beta$ -cyclodextrin tosylate was prepared by stirring mono-6-tosyl- $\beta$ -cyclodextrin with alkylimidazole in DMF at 90 °C for 2 days in very good yields.

10 Allyl and alkylammonium- $\beta$ -cyclodextrin tosylates were prepared by refluxing mono-6-tosyl- $\beta$ -cyclodextrin or mono-2-tosyl- $\beta$ -cyclodextrin with allylamine, propylamine, pentylamine in DMF at 90 °C for 5 hours or 6 days in very good yields.

15 The tosylate anion could be exchanged with other anions by ion-exchange using Amberlite resin.

**Example 1. Synthesis of 6-deoxy-6-(methylimidazolium)- $\beta$ -cyclodextrin tosylate.**

20 A mixture of 6-O-tosyl- $\beta$ -cyclodextrin (12.892g, 0.01 mol) and an excess of 1-methylimidazole (5.0 g, 0.061 mol) was stirred under nitrogen at 90 °C for 2 days. Excess 1-methylimidazole was then removed under vacuum to give light yellow paste. Acetone was added to the light yellow paste and stirred for 30 minutes to allow a solid to form. The pale 25 solid was filtered and washed with acetone followed by drying under high vacuum to afford a white solid (13.50 g, 98.5 %); mp. 257 °C (dec.).

IR (KBr)  $\nu$ : 3399, 2927, 1638, 1600, 1413, 1335, 1305, 1155, 1080, 1032, 943, 843, 754, 683, 577  $\text{cm}^{-1}$ . MS (ESI,

m/e, relative intensity %), 1199.60 (M<sup>+</sup>, 100), calcd. 1199.42; 171.30 (^OTs, 86), calcd. 171.17.

<sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ: 2.30 (s, 3H, CH<sub>3</sub>Ts), 2.82 (t, 1H, J = 6.01 Hz, H-2), 3.06 (t, 1H, J = 6.05 Hz, H-4), 5 3.23 (t, 1H, J = 9.25 Hz, H-5), 3.31-3.47 (m, 12H, H-2,4), 3.50-3.64 (m, 27H, H-3,5,6), 3.85 (s, 3H, CH<sub>3</sub>im), 4.32 (t, 1H, J = 9.24 Hz, OH-6), 4.50 (t, 1H, J = 5.61 Hz, OH-6), 4.56 (t, 4H, J = 5.61 Hz, OH-6), 4.84 (d, 6H, J = 3.21 Hz, H-1), 4.98 (d, 1H, J = 3.60 Hz, H-1), 5.64-5.84 (m, 13H, OH-2,3), 5.99 10 (d, 1H, J = 5.82 Hz, OH-2), 7.13 (d, 2H, J = 8.04 Hz, =CH<sub>meta</sub>), 7.49 (d, 2H, J = 8.40 Hz, =CH<sub>ortho</sub>), 7.68 (s, 1H, =CH-5<sub>im</sub>), 7.69 (s, 1H, =CH-4<sub>im</sub>), 9.01 (s, 1H, =CH-2<sub>im</sub>).

<sup>13</sup>C NMR (125 MHz, DMSO-d<sub>6</sub>) δ: 20.7 (CH<sub>3</sub>Ts), 35.8 (CH<sub>3</sub>im), 49.8 (C6), 59.9 (C6), 69.6 (C5), 72.0 (C5), 72.3 (C3), 15 73.3 (C2), 81.5 (C4), 83.0 (C4), 101.8 (C1), 123.0 (=CH<sub>im</sub>), 123.3 (=CH<sub>im</sub>), 125.4 (C<sub>meta</sub>), 128.0 (C<sub>ortho</sub>), 137.0 (=CH<sub>im</sub>), 137.7 (C<sub>para</sub>), 145.4 (C<sub>ipso</sub>).

**Example 2.** Synthesis of 6-(butylimidazolium)-6-deoxy- $\beta$ -cyclodextrin tosylate.

20 A mixture of 6-O-tosyl- $\beta$ -cyclodextrin (2.578 g, 2.0 mmol) and 1-butyylimidazole (0.745 g, 6.0 mmol) in DMF (5 mL) was stirred under nitrogen at 90 °C for 2 days. After cooling to room temperature, acetone (25 mL) was added to the resultant solution and vigorously stirred for 30 minutes. The 25 solid formed was separated by filtration, washed with acetone and finally dried under vacuum to give a white solid (2.75 g, 96.6 %); mp. 254 °C (dec.).

IR (KBr) ν: 3402, 2929, 1638, 1410, 1335, 1157, 1080, 1033, 945, 844, 756, 683, 578 cm<sup>-1</sup>. MS (ESI, m/e,

relative intensity %), 1241.60 (M<sup>+</sup>, 100), calcd. 1241.47; 171.30 (OTs, 40), calcd. 171.17.

<sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ : 0.90 (t, 3H, J = 7.21 Hz, CH<sub>3</sub>), 1.27 (s, 2H, J = 7.20 Hz, CH<sub>2</sub>), 1.78 (q, 2H, J = 7.02 Hz, CH<sub>2</sub>), 2.29 (s, 3H, CH<sub>3</sub>Ts), 2.83-2.89 (m, 1H, H-2'CD), 3.04-3.07 (m, 1H, H-4'CD) 3.22 - 3.38 (overlap with HDO, m, 12H, H-2<sub>CD</sub> and H-4<sub>CD</sub>), 3.54-3.64 (m, 25H, H-5<sub>CD</sub>, H-3<sub>CD</sub> and H-6<sub>CD</sub>), 3.83 (t, 2H, CH<sub>2</sub>), 4.00 (t, 1H, J = 10.5 Hz, H-5'CD), 4.14 (t, 2H, J = 6.63 Hz, H-6'CD), 4.30 (t, 1H, J = 8.82 Hz, OH-6), 4.47 (t, 2H, J = 5.22 Hz, OH-6), 4.54 (t, 3H, J = 5.19 Hz, OH-6), 4.85 (d, 6H, J = 3.21 Hz, H-1), 4.97 (d, 1H, J = 3.60 Hz, H-1), 5.63-5.84 (m, 13H, OH-2 and OH-3), 5.98 (d, 1H, J = 6.03 Hz, OH-2), 7.12 (d, 2H, J = 8.04 Hz, =CH<sub>meta</sub>), 7.48 (d, 2H, J = 7.62 Hz, =CH<sub>ortho</sub>), 7.72 (s, 1H, =CH-5<sub>im</sub>), 7.78 (s, 1H, =CH-4<sub>im</sub>), 9.09 (s, 1H, =CH-2<sub>im</sub>).

<sup>13</sup>C NMR (125 MHz, DMSO-d<sub>6</sub>) δ: 13.2 (CH<sub>3</sub>), 18.8 (CH<sub>2</sub>), 20.7 (CH<sub>3</sub>), 30.6 (CH<sub>2</sub>), 31.0 (CH<sub>2</sub>), 49.9 (C6'), 59.9 (C6), 69.6 (C5'), 71.7 (C5), 72.4 (C3), 73.0 (C2), 81.5 (C4), 83.2 (C4'), 101.9 (C1), 122.2 (=CH<sub>im</sub>), 123.1 (=CH<sub>im</sub>), 125.4 (C<sub>meta</sub>), 128.0 (C<sub>ortho</sub>), 136.6 (=CH<sub>im</sub>), 137.5 (C<sub>para</sub>), 145.7 (C<sub>ipso</sub>).

**Example 3. Synthesis of 6-deoxy-6-(octylimidazolium)- $\beta$ -cyclodextrin tosylate.**

A mixture of 6-O-tosyl- $\beta$ -cyclodextrin (2.578 g, 2.0 mmol) and 1-octylimidazole (1.082 g, 6.0 mmol) in DMF (5 mL) was stirred under nitrogen at 90 °C for 2 days. After cooling to room temperature, acetone (25 mL) was added to the resultant solution and vigorously stirred for 30 minutes. The solid formed was separated by filtration, washed with acetone and finally dried under vacuum to give a white solid (2.88 g, 98.0 %); mp. 256 °C (dec.).

IR (KBr)  $\nu$ : 3392, 2926, 1639, 1566, 1410, 1369, 1334, 1301, 1157, 1080, 1033, 943, 846, 756, 685, 575  $\text{cm}^{-1}$ . MS (ESI, m/e, relative intensity %), 1297.80 ( $M^+$ , 100), calcd. 1297.53; 171.30 ( ${}^2\text{OTs}$ , 48), calcd. 171.17.

5  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  : 0.85 (t, 3H,  $J$  = 6.81 Hz,  $\text{CH}_3$ ), 1.24 (m, 10H,  $\text{CH}_2$ ), 1.78 (q, 2H,  $J$  = 7.02 Hz,  $\text{CH}_2$ ), 2.28 (s, 3H,  $\text{CH}_{3\text{Ts}}$ ), 2.83-2.89 (m, 1H, H-2' $_{\text{CD}}$ ), 3.04-3.07 (m, 1H, H-4' $_{\text{CD}}$ ) 3.22 - 3.38 (overlap with HDO, m, 12H, H-2 $_{\text{CD}}$  and H-4 $_{\text{CD}}$ ), 3.53-3.64 (m, 25H, H-5 $_{\text{CD}}$ , H-3 $_{\text{CD}}$  and H-6 $_{\text{CD}}$ ), 3.83 (t, 2H,  $\text{CH}_2$ ), 3.96 (t, 1H,  $J$  = 10.5 Hz, H-5' $_{\text{CD}}$ ), 4.13 (t, 2H,  $J$  = 6.63 Hz, H-6' $_{\text{CD}}$ ), 4.30 (t, 1H,  $J$  = 10.63 Hz, OH-6), 4.44 (s br, 2H, OH-6), 4.54 (s br, 3H, OH-6), 4.82 (s br, 6H, H-1), 4.95 (s br, 1H, H-1), 5.62-5.78 (m, 13H, OH-2 and OH-3), 5.95 (d, 1H,  $J$  = 6.03 Hz, OH-2), 7.11 (d, 2H,  $J$  = 7.62 Hz, = $\text{CH}_{\text{meta}}$ ), 7.47 (d, 2H,  $J$  = 8.01 Hz, = $\text{CH}_{\text{ortho}}$ ), 7.71 (s, 1H, = $\text{CH}$ -5 $_{\text{im}}$ ), 7.77 (s, 1H, = $\text{CH}$ -4 $_{\text{im}}$ ), 9.07 (s, 1H, = $\text{CH}$ -2 $_{\text{im}}$ ).

10  $^{13}\text{C}$  NMR (125 MHz, DMSO- $d_6$ )  $\delta$ : 13.9 ( $\text{CH}_3$ ), 20.7 ( $\text{CH}_3$ ), 22.0 ( $\text{CH}_2$ ), 25.5 ( $\text{CH}_2$ ), 28.2 ( $\text{CH}_2$ ), 28.4 ( $\text{CH}_2$ ), 29.1 ( $\text{CH}_2$ ), 30.6 ( $\text{CH}_2$ ), 31.1 ( $\text{CH}_2$ ), 49.9 (C6'), 59.9 (C6), 69.5 (C5'), 71.6 (C5), 72.4 (C3), 73.0 (C2), 81.5 (C4), 83.1 (C4'), 101.9 (C1), 122.2 (= $\text{CH}_{\text{im}}$ ), 123.0 (= $\text{CH}_{\text{im}}$ ), 125.4 (C<sub>meta</sub>), 128.0 (C<sub>ortho</sub>), 136.6 (= $\text{CH}_{\text{im}}$ ), 137.6 (C<sub>para</sub>), 145.7 (C<sub>ipso</sub>).

Example 4. Synthesis of 6-deoxy-6-{2-(2-ethoxyethoxy)ethylimidazolium}- $\beta$ -cyclodextrin tosylate.

25 A mixture of 6-O-tosyl- $\beta$ -cyclodextrin (2.578 g, 2.0 mmol) and 2-(2-ethoxyethoxy)ethylimidazole (1.105 g, 6.0 mmol) in DMF (5 mL) was stirred under nitrogen at 90 °C for 2 days. After cooling to room temperature, acetone (25 mL) was added to the resultant solution and vigorously stirred for 30 minutes. The solid formed was separated by filtration, washed

with acetone and finally dried under vacuum to give a white solid (2.87 g, 97.4 %); mp. 254 °C (dec.).

IR (KBr)  $\nu$ : 3393, 2928, 1638, 1410, 1368, 1335, 1302, 1157, 1119, 1080, 1033, 943, 845, 755, 683, 608, 577 cm<sup>-1</sup>. MS (ESI, m/e, relative intensity %), 1301.60 (M<sup>+</sup>, 100), calcd. 1301.49; 171.30 (OTs, 94), calcd. 171.17.

<sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  : 1.09 (t, 3H, J = 6.84 Hz, CH<sub>3</sub>), 2.28 (s, 3H, CH<sub>3</sub>OTs), 2.83-2.89 (m, 1H, H-2'CD), 3.04-3.07 (m, 1H, H-4'CD) 3.22 - 3.48 (overlap with HDO, m, 18H, 10 OCH<sub>2</sub>, H-2<sub>CD</sub> and H-4<sub>CD</sub>), 3.51-3.68 (m, 27H, OCH<sub>2</sub>, H-5<sub>CD</sub>, H-3<sub>CD</sub> and H-6<sub>CD</sub>), 3.78 (t, 2H, J = 4.41 Hz, CH<sub>2</sub>), 3.96 (t, 1H, J = 10.5 Hz, H-5'CD), 4.34 (t, 2H, J = 6.63 Hz, H-6'CD), 4.45 (s br, 2H, OH-6), 4.52 (s br, 4H, OH-6), 4.84 (d, 6H, J = 2.82 Hz, H-1), 4.95 (d, 1H, J = 3.21 Hz, H-1), 5.64-5.78 (m, 13H, OH-2 and 15 OH-3), 5.96 (d, 1H, J = 6.42 Hz, OH-2), 7.11 (d, 2H, J = 8.01 Hz, =CH<sub>meta</sub>), 7.48 (d, 2H, J = 8.04 Hz, =CH<sub>ortho</sub>), 7.73 (s, 2H, =CH-4,5<sub>im</sub>), 9.01 (s, 1H, =CH-2<sub>im</sub>).

<sup>13</sup>C NMR (125 MHz, DMSO-d<sub>6</sub>)  $\delta$ : 15.0 (CH<sub>3</sub>), 20.7 (CH<sub>3</sub>), 49.8 (C6'), 59.9 (C6), 65.5 (OCH<sub>2</sub>), 68.0 (OCH<sub>2</sub>), 68.9 (OCH<sub>2</sub>), 20 69.5 (C5'), 71.6 (C5), 72.4 (C3), 73.0 (C2), 81.5 (C4), 83.1 (C4'), 101.9 (C1), 122.6 (=CH<sub>im</sub>), 122.8 (=CH<sub>im</sub>), 125.4 (C<sub>meta</sub>), 128.0 (C<sub>ortho</sub>), 137.0 (=CH<sub>im</sub>), 137.5 (C<sub>para</sub>), 145.7 (C<sub>ipso</sub>).

**Example 5. Synthesis of mono-6-deoxy-6-pyridinium- $\beta$ -cyclodextrin tosylate.**

25 A mixture of mono-6-deoxy-6-(p-toluenesulfonyl)- $\beta$ -cyclodextrin (1.289g, 1.0 mmol) and pyridine (0.237 g, 3.0 mmol) in DMF (5 mL) was stirred under nitrogen at 80 °C for 2 days. After cooling to room temperature, acetone (25 mL) was added to the resultant solution and vigorously stirred for 30 30 minutes. The solid formed was separated by filtration, washed

with acetone and finally dried under vacuum to give white solid (1.163 g, 85.0 %), m.p. 239-241 °C.

IR (KBr)  $\nu$ : 3394, 2925, 1636, 1414, 1369, 1335, 1158, 1080, 1032, 943, 682, 577  $\text{cm}^{-1}$ . MS (ESI, m/e, relative intensity %), 1196.60 ( $M^+$ , 100), calcd. 1196.42; 171.30 ( ${}^2\text{OTs}$ , 100), calcd. 171.01.

$^1\text{H}$  NMR (300 MHz,  $\text{DMSO}-d_6$ )  $\delta$ : 2.29 (s, 3H,  $\text{CH}_3\text{Ts}$ ), 3.12-3.47 (overlap with HDO, m, 14H, H-2<sub>CD</sub> and H-4<sub>CD</sub>), 3.55-3.67 (m, 26H, H-5<sub>CD</sub>, H-3<sub>CD</sub> and H-6<sub>CD</sub>), 3.86-3.96 (m, 2H, H-6<sub>CD</sub>), 4.18 (t, 1H,  $J$  = 10.02, 10.83 Hz, OH-6), 4.28 (t, 1H,  $J$  = 6.03, 5.61 Hz, OH-6), 4.45 (t, 1H,  $J$  = 5.22, 5.61 Hz, OH-6), 4.54 (t, 2H,  $J$  = 5.61, 5.22 Hz, OH-6), 4.60 (t, 1H,  $J$  = 5.61, 7.62 Hz, OH-6), 4.77-4.88 (m, 6H, H-1), 5.02 (d, 1H,  $J$  = 6.0 Hz, H-1), 5.58 (d, 1H,  $J$  = 2.01 Hz, OH-3), 5.63-5.87 (m, 12H, OH-2 and OH-3), 6.06 (d, 1H,  $J$  = 6.0 Hz, OH-2), 7.10 (d, 2H,  $J$  = 7.62 Hz, = $\text{CH}_{\text{metaTs}}$ ), 7.48 (d, 2H,  $J$  = 8.40 Hz, = $\text{CH}_{\text{orthoTs}}$ ), 8.13 (t, 2H,  $J$  = 7.23, 6.84 Hz, = $\text{CH-3}_{\text{pyr}}$ ), 8.64 (t, 1H,  $J$  = 8.04, 7.68 Hz, = $\text{CH-4}_{\text{pyr}}$ ), 9.01 (d, 2H,  $J$  = 6.03 Hz, = $\text{CH-2}_{\text{pyr}}$ ).

$^{13}\text{C}$  NMR (125 MHz,  $\text{DMSO}-d_6$ )  $\delta$ : 20.7 ( $\text{CH}_3\text{Ts}$ ), 58.7 (C6'), 20 59.8 (C6), 60.8 (C6), 61.6 (C6), 70.2 (C5'), 71.3, 71.9, 72.1, 72.3, 73.0, 73.4 (C5, C3, C2), 80.6, 81.4, 82.9 (C4), 83.6 (C4'), 100.9 (C1'), 101.8, 101.9, 102.3 (C1), 125.4 (C<sub>metaTs</sub>), 127.9 (C3<sub>pyr</sub>), 128.0 (C<sub>orthoTs</sub>), 137.5 (C<sub>paraTs</sub>), 145.4 (C<sub>ipsoTs</sub>), 145.5 (C4<sub>pyr</sub>), 146.1 (C2<sub>pyr</sub>).

25

**Example 6.** Synthesis of mono-6-allylammonium-6-deoxy- $\beta$ -cyclodextrin tosylate.

A solution of mono-6-deoxy-6-(p-toluenesulfonyl)- $\beta$ -cyclodextrin (2.578 g, 2.0 mmol) and allylamine (0.343 g, 6.0 mmol) in dimethyl formamide (5 mL) was refluxed for 5 hours

under nitrogen. After cooling to room temperature, acetone (25 mL) was added to the resultant solution and stirred for 30 minutes. The white solid formed was filtered and dried under vacuum over night to give the desired product (2.48 g, 92.1 %); mp. 249 °C (dec.).

IR (KBr)  $\nu$ : 3426, 2926, 1638, 1445, 1411, 1334, 1157, 1080, 1032, 943, 760, 700, 639, 575  $\text{cm}^{-1}$ . MS (ESI, m/e, relative intensity %), 1174.40 ( $\text{MH}^+$ , 100), calcd. 1174.42; 171.30 ( $\text{^OTs}$ , 26), calcd. 171.17.

$^1\text{H}$  NMR (500 MHz,  $\text{DMSO}-d_6$ )  $\delta$  : 2.29 (s, 3H,  $\text{CH}_3\text{Ts}$ ), 2.85 (t, 1H,  $J$  = 8.82 Hz, H-2'<sub>CD</sub>), 3.10 (d, 1H,  $J$  = 12.05 Hz, H-4'<sub>CD</sub>) 3.32 - 3.54 (overlap with HDO, m, 14H, H-2<sub>CD</sub>, H-4<sub>CD</sub> and  $\text{CH}_2$ ), 3.60-3.63 (m, 27H, H-5<sub>CD</sub>, H-3<sub>CD</sub> and H-6<sub>CD</sub>), 3.80 (t, 1H, H-3'<sub>CD</sub>), 4.50 (s br, 1H, OH-6), 4.83 (d, 6H,  $J$  = 3.65 Hz, H-1), 4.87 (d, 1H,  $J$  = 3.25 Hz, H-1), 5.16-5.38 (m, 2H, = $\text{CH}_2$ ), 5.67 (s br, 6H, OH-3), 5.73 (s br, 8H, OH-2 and OH-3), 5.81-5.87 (m, 1H, -CH=), 7.12 (d, 2H,  $J$  = 8.30 Hz, = $\text{CH}_{\text{meta}}$ ), 7.48 (d, 2H,  $J$  = 7.85 Hz, = $\text{CH}_{\text{ortho}}$ ).

$^{13}\text{C}$  NMR (125 MHz,  $\text{DMSO}-d_6$ )  $\delta$ : 20.7 ( $\text{CH}_3$ ), 40.9 ( $\text{CH}_2$ ), 50.6 (C6'), 59.9 (C6), 69.0 (C5'), 72.0 (C5), 72.2 (C3), 73.0 (C2), 81.2 (C4), 83.6 (C4'), 101.9 (C1), 119.8 (= $\text{CH}_2$ ), 125.4 (C<sub>meta</sub>), 128.1 (C<sub>ortho</sub>), 130.8 (-CH=), 137.9 (C<sub>para</sub>), 145.1 (C<sub>ipso</sub>).

**Example 7.** Synthesis of mono-6-deoxy-6-(*n*-propylammonium)- $\beta$ -cyclodextrin tosylate.

A solution of mono-6-deoxy-6-(*p*-toluenesulfonyl)- $\beta$ -cyclodextrin (2.578 g, 2.0 mmol) and *n*-propylamine (0.355 g, 6.0 mmol) in dimethyl formamide (5 mL) was refluxed for 5 hours under nitrogen. After cooling to room temperature, acetone (25 mL) was added to the resultant solution and stirred for 30 minutes. The white solid formed was filtered

and dried under vacuum over night to give the desired product (2.64 g, 97.9 %); mp. 260 °C (dec.).

IR (KBr)  $\nu$ : 3397, 2928, 1638, 1410, 1334, 1301, 1155, 1080, 1032, 943, 759, 702, 577  $\text{cm}^{-1}$ . MS (ESI, m/e, 5 relative intensity %), 1176.50 ( $\text{MH}^+$ , 100), calcd. 1176.44; 171.30 ( ${}^2\text{OTs}$ , 14), calcd. 171.17.

$^1\text{H}$  NMR (500 MHz,  $\text{DMSO}-d_6$ )  $\delta$  : 0.85 (t, 3H,  $J$  = 7.62 Hz,  $\text{CH}_3$ ), 1.48 (s, 2H,  $J$  = 7.23 Hz,  $\text{CH}_2$ ), 2.29 (s, 3H,  $\text{CH}_{3\text{Ts}}$ ), 2.63 (t, 2H,  $J$  = 7.23 Hz,  $\text{CH}_2$ ), 2.89 (t, 1H,  $J$  = 8.82 Hz, H-10 2'CD), 3.12 (d, 1H,  $J$  = 11.62 Hz, H-4'CD) 3.34 - 3.44 (overlap with HDO, m, 14H, H-2CD and H-4CD), 3.54-3.63 (m, 27H, H-5CD, H-3CD and H-6CD), 3.78 (t, 1H, H-3'CD), 4.48 (s br, 6H, OH-6), 4.83 (s, 6H, H-1), 4.86 (s, 1H, H-1), 5.67-5.79 (m, 14H, OH-2 and OH-3), 7.12 (d, 2H,  $J$  = 8.04 Hz, = $\text{CH}_{\text{meta}}$ ), 7.48 (d, 2H,  $J$  = 15 7.62 Hz, = $\text{CH}_{\text{ortho}}$ ).

$^{13}\text{C}$  NMR (125 MHz,  $\text{DMSO}-d_6$ )  $\delta$ : 11.2 ( $\text{CH}_3$ ), 20.7 ( $\text{CH}_3$ ), 30.6 ( $\text{CH}_2$ ), 34.5 ( $\text{CH}_2$ ), 50.2 (C6'), 59.9 (C6), 69.0 (C5'), 72.0 (C5), 72.4 (C3), 73.0 (C2), 81.5 (C4), 83.5 (C4'), 101.9 (C1), 125.4 (Cmeta), 128.0 (Cortho), 137.7 (Cpara), 145.4 (Cipso).

20 **Example 8.** Synthesis of mono-6-deoxy-6-(n-butylammonium)- $\beta$ -cyclodextrin tosylate.

A solution of mono-6-deoxy-6-(p-toluenesulfonyl)- $\beta$ -cyclodextrin (2.578 g, 2.0 mmol) and n-butylamine (0.349 g, 6.0 mmol) in dimethyl formamide (5 mL) was refluxed at 90 °C 25 for 5 hours under nitrogen. After cooling to room temperature, acetone (25 mL) was added to the resultant solution and stirred for 30 minutes. The white solid formed was filtered and dried under vacuum over night to give the desired product (2.65 g, 97.3 %); mp. 263 °C (dec.).

IR (KBr)  $\nu$ : 3382, 2928, 1640, 1415, 1369, 1335, 1302, 1157, 1080, 1032, 943, 756, 704, 576  $\text{cm}^{-1}$ . MS (ESI, m/e, relative intensity %), 1190.40 ( $\text{MH}^+$ , 100), calcd. 1190.46; 171.30 ( ${}^2\text{OTs}$ , 28), calcd. 171.17.

5  $^1\text{H}$  NMR (500 MHz,  $\text{DMSO}-d_6$ )  $\delta$  : 0.85 (t, 3H,  $J$  = 7.23 Hz,  $\text{CH}_3$ ), 1.27 (s, 2H,  $J$  = 7.65 Hz,  $\text{CH}_2$ ), 1.41 (s, 2H,  $J$  = 7.62 Hz,  $\text{CH}_2$ ), 2.28 (s, 3H,  $\text{CH}_3\text{Ts}$ ), 2.61 (t, 2H,  $J$  = 7.64 Hz,  $\text{CH}_2$ ), 2.83 (t, 1H,  $J$  = 8.82 Hz,  $\text{H}-2'\text{CD}$ ), 3.07 (d, 1H,  $J$  = 11.22 Hz,  $\text{H}-4'\text{CD}$ ) 3.31 - 3.46 (overlap with  $\text{HDO}$ , m, 12H,  $\text{H}-2\text{CD}$  and  $\text{H}-4\text{CD}$ ), 10 3.54-3.63 (m, 27H,  $\text{H}-5\text{CD}$ ,  $\text{H}-3\text{CD}$  and  $\text{H}-6\text{CD}$ ), 3.75 (t, 1H,  $\text{H}-3'\text{CD}$ ), 4.50 (s br, 6H,  $\text{OH}-6$ ), 4.83 (s, 6H,  $\text{H}-1$ ), 4.85 (s, 1H,  $\text{H}-1$ ), 5.64-5.81 (m, 14H,  $\text{OH}-2$  and  $\text{OH}-3$ ), 7.12 (d, 2H,  $J$  = 8.04 Hz,  $=\text{CH}_{\text{meta}}$ ), 7.48 (d, 2H,  $J$  = 8.04 Hz,  $=\text{CH}_{\text{ortho}}$ ).

15  $^{13}\text{C}$  NMR (125 MHz,  $\text{DMSO}-d_6$ )  $\delta$ : 13.7 ( $\text{CH}_3$ ), 19.6 ( $\text{CH}_2$ ), 20.7 ( $\text{CH}_3$ ), 30.6 ( $\text{CH}_2$ ), 48.3 ( $\text{C}6'$ ), 59.8 ( $\text{C}6$ ), 69.2 ( $\text{C}5'$ ), 72.0 (C5), 72.4 (C3), 73.0 (C2), 81.5 (C4), 83.5 (C4'), 101.9 (C1), 125.4 ( $\text{C}_{\text{meta}}$ ), 128.0 ( $\text{C}_{\text{ortho}}$ ), 137.7 ( $\text{C}_{\text{para}}$ ), 145.4 ( $\text{C}_{\text{ipso}}$ ).

**Example 9.** Synthesis of mono-6-deoxy-6-(n-pentylammonium)- $\beta$ -cyclodextrin tosylate.

20 A solution of mono-6-deoxy-6-(p-toluenesulfonyl)- $\beta$ -cyclodextrin (2.578 g, 2.0 mmol) and n-pentylamine (0.532 g, 6.0 mmol) in dimethyl formamide (5 mL) was refluxed at 90 °C for 5 hours under nitrogen. After cooling to room temperature, acetone (25 mL) was added to the resultant solution and stirred for 30 minutes. The white solid formed was filtered and dried under vacuum over night to give the desired product (2.65 g, 96.3 %); 266 °C (dec.).

IR (KBr)  $\nu$ : 3402, 2922, 1639, 1418, 1370, 1335, 1302, 1157, 1080, 1031, 943, 755, 705, 577  $\text{cm}^{-1}$ . MS (ESI, m/e,

relative intensity %), 1204.50 (MH<sup>+</sup>, 100), calcd. 1204.47; 171.3 (^OTs, 16), calcd. 171.17.

5       <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ : 0.86 (t, 3H, J = 6.42 Hz, CH<sub>3</sub>), 1.25 (s br, 4H, CH<sub>2</sub>), 1.47 (s br, 2H, CH<sub>2</sub>), 2.29 (s, 3H, CH<sub>3</sub><sub>Ts</sub>), 2.63 (t, 2H, CH<sub>2</sub>), 2.85 (t, 1H, H-2'<sub>CD</sub>), 3.12 (d, 1H, J = 11.22 Hz, H-4'<sub>CD</sub>) 3.32 - 3.45 (overlap with HDO, m, 12H, H-2<sub>CD</sub> and H-4<sub>CD</sub>), 3.54-3.65 (m, 27H, H-5<sub>CD</sub>, H-3<sub>CD</sub> and H-6<sub>CD</sub>), 3.75 (t, 1H, H-3'<sub>CD</sub>), 4.48 (s br, 6H, OH-6), 4.84 (s, 6H, H-1), 4.86 (s, 1H, H-1), 5.66-5.81 (m, 14H, OH-2 and OH-3), 7.12 (d, 2H, J = 8.43 Hz, =CH<sub>meta</sub>), 7.48 (d, 2H, J = 8.04 Hz, =CH<sub>ortho</sub>).

10       <sup>13</sup>C NMR (125 MHz, DMSO-d<sub>6</sub>) δ: 13.8 (CH<sub>3</sub>), 20.7 (CH<sub>3</sub>), 21.8 (CH<sub>2</sub>), 28.5 (CH<sub>2</sub>), 30.6 (CH<sub>2</sub>), 48.3 (C6'), 59.9 (C6), 68.8 (C5'), 72.0 (C5), 72.4 (C3), 73.0 (C2), 81.4 (C4), 83.5 (C4'), 101.9 (C1), 125.4 (C<sub>meta</sub>), 128.1 (C<sub>ortho</sub>), 137.9 (C<sub>para</sub>), 145.1 (C<sub>ipso</sub>).

**Example 10.** Synthesis of mono-2-allylammonium-2-deoxy- $\beta$ -cyclodextrin tosylate.

20       A solution of mono-2-deoxy-2-(*p*-toluenesulfonyl)- $\beta$ -cyclodextrin (1.289 g, 1.0 mmol) and allyl amine (2 g, 35.0 mmol) in dimethyl sulfoxide (3 mL) was refluxed for 6 days under nitrogen. The resultant solution was cooled to room temperature, added with acetone (25 mL) and stirred for 30 minutes. The white solid formed was filtered and dried under vacuum over night to give a desired product (1.25 g, 92.9 %); 25 mp. 250 °C (dec.).

IR (KBr) ν: 3438, 2929, 1639, 1448, 1413, 1335, 1158, 1079, 1031, 942, 761, 701, 640, 574 cm<sup>-1</sup>. MS (ESI, m/e, relative intensity %), 1174.40 (MH<sup>+</sup>, 100), calcd. 1174.42; 171.30 (^OTs, and 26), calcd. 171.01.

5       <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ: 2.29 (s, 3H, CH<sub>3</sub>), 3.25-3.46 (m, 14H, CH-2,4 overlap with HOD), 3.55-3.98 (m, 28H, CH-3,5,6) 4.37-4.65 (m, 7H, OH-6), 4.80-4.95 (m, 7H, CH-1), 5.16 (d, 1H, J = 10.2 Hz, OH-3), 5.30 (1H, d, J = 17.1 Hz, OH-3), 5.56-5.60 (m, 2H, =CH<sub>2</sub>), 5.63-5.80 (m, 12H, OH-2,3), 5.81-5.86 (m, 1H, -CH=), 7.11 (d, 2H, J = 7.85 Hz, =CH<sub>meta</sub>-aromatic), 7.48 (d, 2H, J = 8.30 Hz, =CH<sub>ortho</sub>-aromatic).

10       <sup>13</sup>C NMR (125 MHz, DMSO-d<sub>6</sub>) δ: 20.8 (CH<sub>3</sub>), 30.7 (CH<sub>2</sub>), 48.8 (C-6), 58.2 (C-6), 59.7 (C-6), 70.1 (C-5), 71.7-73.3 (m, C-2,3,5), 75.3 (C-3), 76.8 (C-2), 79.9 (C-4), 81.0-82.0 (m, C-4), 101.6-102.2 (m, C-1), 103.8 (C-1), 125.5 (=CH<sub>2</sub>), 128.0 (C<sub>meta</sub>), 130.9 (C<sub>ortho</sub>), 137.6 (-CH=), 137.6 (C<sub>para</sub>), 145.7 (C<sub>ipso</sub>).

**Example 11.** Synthesis of mono-2-deoxy-2-(*n*-propylammonium)- $\beta$ -cyclodextrin tosylate.

15       A solution of mono-2-deoxy-2-(*p*-toluenesulfonyl)- $\beta$ -cyclodextrin (6.20 g, 4.81 mmol) and *n*-propyl amine (9.950 g, 168.3 mmol) in dimethyl sulfoxide (10 mL) was refluxed for 6 days under nitrogen. The resultant solution was cooled to room temperature, added with acetone (50 mL) and stirred for 30 minutes. The white solid formed was filtered and dried under vacuum over night to give a desired product (5.95 g, 91.7 %); mp. 255 °C (dec.).

25       IR (KBr) ν: 3395, 2929, 1639, 1411, 1335, 1302, 1154, 1079, 1033, 944, 758, 701, 576 cm<sup>-1</sup>. MS (ESI, m/e, relative intensity %), 1176.70 (MH<sup>+</sup>, 100), calcd. 1176.44; 171.30 (^OTs, and 26), calcd. 171.01.

30       <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ: 0.87 (t, 3H, J = 7.23 Hz, CH<sub>3</sub>), 1.54 (q, 2H, J = 7.23 Hz, CH<sub>2</sub>), 2.28 (s, 3H, CH<sub>3</sub>), 3.29-3.41 (m, 15H, CH<sub>2</sub>, CH-2 and CH-4 overlap with HOD), 3.54-3.70 (m, 27H, CH-5, CH-3, CH-6), 3.98 (d, 1H, J = 12.45 Hz, CH-3 with <sup>1</sup>NH<sub>2</sub> group), 4.46 (s, br, 7H, OH-6), 4.67 (d, 1H, J = 6.81

Hz, CH-2 with <sup>15</sup>NH<sub>2</sub> group), 4.82 (d, 6H, J = 2.82 Hz, CH-1), 4.91 (d, 1H, J = 3.60 Hz, CH-1 with <sup>15</sup>NH<sub>2</sub> group), 5.60 (t, 1H, J = Hz, OH-3), 5.67 (s, 6H, OH-2), 5.70 (t, 5H, J = 6.42 Hz, OH-3), 5.85 (s, br, 1H, OH-3 with <sup>15</sup>NH<sub>2</sub> group), 7.11 (d, 2H, J = 8.04 Hz, =CH<sub>meta</sub>-aromatic), 7.48 (d, 2H, J = 8.04 Hz, =CH<sub>ortho</sub>-aromatic).

<sup>13</sup>C NMR (125 MHz, DMSO-d<sub>6</sub>) δ: 11.3 (CH<sub>3</sub>), 20.5 (CH<sub>2</sub>), 20.8 (CH<sub>3</sub>), 48.1 (CH<sub>2</sub>), 58.9 (C-6'), 59.8-60.2 (m, C-6), 69.6 (C-5'), 71.7-73.2 (m, C-2, C-3, C-5), 74.9 (C-3'), 76.6 (C-2'), 79.7 (C-4'), 81.0-82.0 (m, C-4), 101.6-102.2 (m, C-1), 103.6 (C-1'), 124.5 (C-3,5<sub>Ts</sub>), 128.0 (C-2,6<sub>Ts</sub>), 137.6 (C-4<sub>Ts</sub>), 145.7 (C-1<sub>Ts</sub>).

**Example 12. Synthesis of mono-6-deoxy-6-(dimethyl n-butyl ammonium) permethylated  $\beta$ -cyclodextrin iodide**

In a three-neck, 250 mL round-bottomed flask equipped with a condenser, nitrogen inlet, stopper and magnetic stirrer was placed mono-6-deoxy-6-n-butylammonium- $\beta$ -cyclodextrin (6.82 g, 5 mmol) obtained in Experiment 8, which had been dried at 60 °C for 1 d under vacuum, and dry dimethylformamide (100 mL). The solution was stirred and cooled to 0 °C by ice-acetone bath and then sodium hydride (5.28 g, 0.22 mol, 60 % dispersion in mineral oil) was added. After maintaining the temperature for 2 h, methyl iodide (14.0 mL, 0.22 mol) was added and the mixture was stirred at 0 °C for 1 h. The temperature was raised to 10 °C and continuous stirred for 1 h and then to room temperature for 3 h. After the addition of ethanol (18 mL) and saturated aqueous sodium chloride solution (200 mL) containing Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub>, the mixture was extracted with ethyl acetate (3 x 200 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> overnight, filtered and removed by rotatory evaporator followed by high vacuum overnight to give a foam solid (7.30 g, 89.8 %), mp. 79.0-81.0 °C.

IR (KBr)  $\nu$ : 2931, 2831, 1654, 1462, 1370, 1323, 1159, 1105, 1038, 970, 908.5, 856, 752, 705, 565  $\text{cm}^{-1}$ . MS (ESI, m/e, relative intensity %) 1498.9 ( $M^+$ , 100), calcd. 1498.8; 126.8 ( $I^-$ , 100), calcd. 126.9.

5  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  0.93 (t, 3H,  $J$  = 7.20 Hz,  $\text{CH}_3$ ), 1.36 (q, 2H,  $J$  = 7.23 Hz,  $\text{CH}_2$ ), 1.70 (q, 2H,  $J$  = 6.84,  $\text{CH}_2$ ), 3.06 – 3.21 (m, 7H, H-2), 3.27 – 3.57 (m, 29H, H-3,4,5,  $\text{CH}_2\text{N}(\text{CH}_3)_2$ ), 3.30 (s, 21H,  $\text{OCH}_3$ ), 3.41 (s, 18H,  $\text{OCH}_3$ ), 3.52 (s, 21H,  $\text{OCH}_3$ ), 3.61 – 3.78 (m, 12H, H-6), 4.25 (t, 2H,  $J$  = 8.82 Hz, H-6), 4.91 – 5.10 (m, 7H, H-1).

10  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  13.7 ( $\text{CH}_3$ ), 19.3 ( $\text{CH}_2$ ), 24.7 ( $\text{CH}_2$ ), 51.8 ( $\text{NCH}_2$ ), 57.8 – 61.2 (m,  $\text{OCH}_3$ ), 64.1 (C-5), 65.9 (C-5), 68.1 (C-5), 70.6 – 71.7 (m, C-5,6), 72.8 (C-6), 75.9 (C-6), 78.4 (C-4), 80.0 – 82.4 (m, C-4,2,3), 96.0 (C-1), 97.9 (C-1), 98.8 (C-1), 99.1 (C-1), 99.2 (C-1), 99.7 (C-1).

**Example 13. Synthesis of mono-6-amino-6-deoxy- $\beta$ -cyclodextrin.**

A mixture of mono-6-azido-6-deoxy- $\beta$ -cyclodextrin (5.80 g, 5 mmol), prepared from 6-O-tosyl- $\beta$ -cyclodextrin using previously reported procedure by R. S. Petter, J. S. Salek, C. 20 T. Sikorski, G. Kumaravel and F-T. Lin [16], and triphenyl phosphine (1.443 g, 5.5 mmol) in DMF (10 mL) was stirred at room temperature for 2 hours. The resultant solution was added deionized water (1.0 mL) and reflux for 2 hours. The solution was added acetone to precipitate the white solid and the solid 25 was filtered, washed with acetone and finally dried under high vacuum for overnight to give pure product 5.50 g (97.0 %), mp. 275-277 °C (dec.).

IR (KBr)  $\nu$ : 3428, 3311, 2928, 1659, 1438, 1414, 1389, 1369, 1334, 1156, 1080, 1030, 947, 755, 707, 609, 580  $\text{cm}^{-1}$ . MS

(ESI, m/e, relative intensity %), 1134.50 (M+H<sup>+</sup>, 100), calcd. 1134.30.

<sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ: 3.34 (m, 30H, H-3,5, H-6, NH<sub>2</sub>), 3.56-3.65 (m, 14H, H-2,4), 4.43-4.46 (m, 6H, OH-6), 4.83 (d, 6H, J = 2.0 Hz, H-1), 4.89 (d, 1H, J = 2.0 Hz, H-1<sup>A</sup>), 5.61-5.77 (m, 14H, OH-2,3).

<sup>13</sup>C NMR (75 MHz, DMSO-d<sub>6</sub>) δ: 59.9 (C-6), 72.0 (C2), 72.4 (C-3), 73.0 (C-5), 81.6, 82.3 (C-4), 101.9 (C-1).

**Example 14.** Synthesis of mono-6-deoxy-6-(trimethyl ammonium) permethylated  $\beta$ -cyclodextrin iodide.

In a three-neck, 250 mL round-bottomed flask equipped with a condenser, nitrogen inlet, stopper and magnetic stirrer was placed mono-6-amino-6-deoxy- $\beta$ -cyclodextrin (2.268 g, 2.0 mmol) obtained in Experiment 13, which had been dried at 60 °C for 1 d under vacuum, and dry dimethylformamide (50 mL). The solution was stirred and cooled to 0 °C by ice-acetone bath and then sodium hydride (3.68 g, 92.0 mmol, 60 % dispersion in mineral oil) was added. After maintaining the temperature for 2 h, methyl iodide (13.058 g, 92.0 mmol) was added and the mixture was stirred at 0 °C for 1 h. The temperature was raised to 10 °C and continuous stirred for 1 h and then to room temperature for 3 h. After the addition of ethanol (5 mL) and saturated aqueous sodium chloride solution (100 mL) containing Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub>, the mixture was extracted with ethyl acetate (3 x 100 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> overnight, filtered and removed by rotatory evaporator followed by high vacuum overnight to give a foam solid (2.67 g, 84.2 %), mp. 89.5 - 91.5 °C.

IR (KBr) ν: 2929, 2833, 1459, 1369, 1232, 1192, 1159, 30 1103, 1037, 970, 893, 854, 752, 705, 555 cm<sup>-1</sup>. MS (ESI, m/e,

relative intensity %), 1456.90 (M<sup>+</sup>, 100), calcd. 1456.75; 127.30 (I<sup>-</sup>, 100), calcd. 126.91.

5 <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 1.24 (s, 9H, CH<sub>3</sub>), 3.15-3.27 (m, 7H, H-5), 3.33-3.70 (m, 21H, H-3, 6) 3.36-3.40 (m, 18H, OCH<sub>3</sub>), 3.42-3.58 (m, 21H, OCH<sub>3</sub>), 3.60-3.63 (m, 21H, OCH<sub>3</sub>), 3.72-3.90 (m, 12H, H-2, 4), 4.10 (t, 1H, J = 4.31 Hz, H-4), 4.33 (t, 1H, J = 5.67 Hz, H-4), 4.98-5.22 (m, 7H, H-1).

10 <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ: 29.6 (CH<sub>3</sub>), 54.6, 58.0-61.4 (m, 2-CH<sub>3</sub>, 6-CH<sub>3</sub>, 3-CH<sub>3</sub>), 67.4, 68.3, 70.7-71.8 (m, C-5, C-6), 76.4, 78.3, 80.2-82.1 (m, C-4, C-3, C-3), 83.7, 96.1, 98.1, 98.9, 99.2, 99.4, 99.8, 100.1 (C-1).

**Example 15.** Synthesis of 6-deoxy-6-(methylimidazolium)- $\beta$ -cyclodextrin chloride, (example of exchange of <sup>1</sup>OTs with other anions).

15 Mono-6-deoxy-6-(methylimidazolium)- $\beta$ -cyclodextrin tosylate obtained in Experiment 1 (1.09 g, 0.8 mmol) was dissolved in 50ml deionised water. An amberlite 900 (Cl) resin was used for anionic exchange to obtain a yellow crystalline solid (0.982 g, 100%); mp. 226.8-227.8 °C (dec.).

20 Elemental analysis, Calcd C: 42.84%, H: 6.34% N: 2.17% S: 2.75%, Found C: 42.83% H: 5.97% N: 2.22% S: 2.87%; MALDI-TOF: 1199.1831 (M<sup>+</sup>], Calcd. 1200.1920; IR (KBr) ν: 3410.4, 1639.7, 1410, 1158.1, 1079.8, 1030.0, 998.6 cm<sup>-1</sup>.

25 <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ: 3.23 - 3.49 (m, overlap with water-shift of DMSO-d6, m, 15H,  $\beta$ CD H-2 & H-4, imidazolium N-CH<sub>3</sub>), 3.54 - 3.84 (m, 24H,  $\beta$ CD H-6<sub>a</sub>, b, H-3 & H-5), 4.49 - 4.57 (m, 5H,  $\beta$ CD OH-6), 4.77 - 4.97 (m, 6H,  $\beta$ CD H-1), 5.66 - 5.81 (m, 12H,  $\beta$ CD OH-2 & OH-3), 7.70 (s, 2H, imidazolium C4-H, C5-H), 9.07 (s, 1H, imidazolium C2-H).

<sup>13</sup>C NMR (100 MHz, DMSO-d<sub>6</sub>) δ: 137.08, 123.34, 123.01 (imidazolium C2, C5 & C4 respectively), 101.86 (βCD C1), 81.45 (βCD C4), 72.78 (βCD C3), 72.11 (βCD C2), 71.96 (βCD C5), 59.84 (βCD C6), 35.79 (imidazolium N-C).

5 Example 16. Application of the ionic CDs in asymmetric synthesis.

A solution of 6-deoxy-6-(methylimidazolium)- $\beta$ -cyclodextrin tosylate (2.0 g, 1.458 mmol) in water/MeOH (5 ml : 2 mL) and 4-fluorobenzaldehyde (0.180 g, 1.458 mmol) was 10 stirred for 24 hours to form an inclusion complex. Tetraallyltin (0.103 g, 0.365 mmol) was added to the complex and stirred for 24 hours at room temperature. The reaction mixture was extracted with dichloromethane (3x5 mL) and the dichloromethane layer was dried (Na<sub>2</sub>SO<sub>4</sub> anhydrous) and 15 evaporated off. The residue was purified by kugelrohr distillation to give the desired product (0.210 g, 86.64 %), oven temp. 100 °C/2.0 mm Hg.

20 <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ: 1.87 (bs, 1H, OH), 2.41-2.54 (m, 2H, CH<sub>2</sub>), 4.72 (dd, J = 5.6, 7.2 Hz, 1H, CHOH), 5.12-5.19 (m, 2H, CH=CH<sub>2</sub>), 5.72-5.86 (m, 1H, CH=CH<sub>2</sub>), 7.03 (t, J = 8.8 Hz, 2H, aromatic H<sub>m</sub>), 7.33 (dd, J<sub>HH</sub> = 8.4 Hz, J<sub>HF</sub> = 5.6 Hz, 2H, aromatic H<sub>o</sub>). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>, δ: 43.6 (C2), 72.7 (C1), 115.0 (C4), 118.2 (C3), 127.5 (C3'), 134.1 (C2'), 139.6 (C1'), 162.0 (C4')).

25 While particular embodiments of the present invention have been described in the foregoing, it is to be understood that other embodiments are possible within the scope of the invention and are intended to be included herein. The invention is to be considered limited solely by the scope 30 of the appended claims.

## REFERENCES

1. E. Schneiderman and A. M. Stalcup, *J. Chromatogr. B*, 2000, 745, 83-102.
2. Z. Juvancz, *TrAC.*, 2002, 21(5), 379-388.
- 5 3. K. W. Phinney and L.C. Sander, *Anal. Bioanal. Chem.*, 2002, 372, 101-108.
4. S. Wren, *Chromatographia*, 2001, 54, S5-S96.
5. R. Bressole, M. Audran, T. N. Pham, and J. J. Vallon, *J. Chromatogr. B*, 1996, 687, 303-336.
- 10 6. J. Szeman, K. Ganzler, A. Salgo, and J. Szejtli, *J. Chromatogr. A*, 1996, 728, 423-431.
7. P. K. Owens, A. F. Fell, M. W. Coleman, and J. C. Berridge, *J. Chromatogr. A*, 1998, 797, 149-164.
- 15 8. P. K. Owens, A. F. Fell, M. W. Coleman, and J. C. Berridge, *J. Chromatogr. A*, 1998, 797, 187-195.
9. S. A. C. Wren and R. C. Rowe, *J. Chromatogr.* 1992, 603, 235-241.
10. S. Terabe, K. Otsuka and H. Nishi, *J. Chromatogr. A*, 1994, 666, 295-319.
- 20 11. S. Terabe, H. Ozaki, K. Otsuka, and T. Ando, *J. Chromatogr.* 1985, 332, 211.
12. S. Fanali and Z. Aturki, *J. Chromatogr. A*, 1995, 694, 297-305.
13. Y. Tanaka, *Chromatography*, 2002, 23 (1), 13-23.

14. Y. Tanaka and S. Terabe, *J. Chromatogr. A*, 1997, 781, 151-160.

15. Y. Matsui and A. Okimoto, *Bull. Chem. Soc. Jpn.*, 1978, 51, 3030-3034.

5 16. R. S. Petter, J. S. Salek, C. T. Sikorski, G. Kumaravel and F-T. Lin, *J. Am. Chem. Soc.*, 1990, 122, 3860-3868.

17. S. Terabe, *TrAC.*, 1989, 8, 129-131.

18. A. Nardi, A. Eliseev, P. Bocek and S. Fanali, *J. Chromatogr.*, 1993, 638, 247-253.

10 19. B. Chankvetadze, G. Schulte, and G. Blaschke, *J. Chromatogr. A.*, 1996, 732, 183-187.

20. U. B. Nair and D. W. Armstrong, *Microchem. Journal*, 1997, 57, 199-217.

15 21. A. R. Khan, P. Forgo, K.J. Stine and V. T. D'Souza, *Chem. Rev.*, 1998, 98, 1977-1996.

22. B. Brady, N. Lynam, T. O'Sullivan, C. Ahern, R. Darcy, *Org. Synth.*, 2000, 77, 220-224.

23. T. Murakami, K. Harata, and S. Morimoto, *Tetrahedron Lett.*, 1987, 28, 321-324.

20